Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last641 to 660 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With Time to Cardiovascular Death | 269 of 6,992 257 of 6,978 | 0.2 points -0.5 to 0.8 | 13,970 | NCT02993406 Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo |
| Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With First Occurrence of Myocardial Infarction | 261 of 6,992 334 of 6,978 | -1.1 points -1.7 to -0.4 | 13,970 | NCT02993406 Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo |
| Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With Time to First Occurrence of Stroke | 135 of 6,992 158 of 6,978 | -0.3 points -0.8 to 0.1 | 13,970 | NCT02993406 Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo |
| Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With First Occurrence of Three Component MACE | 575 of 6,992 663 of 6,978 | -1.3 points -2.2 to -0.3 | 13,970 | NCT02993406 Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo |
| Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With Time to All-cause Mortality | 434 of 6,992 420 of 6,978 | 0.2 points -0.6 to 1.0 | 13,970 | NCT02993406 Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo |
| Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With First Occurrence of Four Component Major Adverse Cardiovascular Events (MACE) | 819 of 6,992 927 of 6,978 | -1.6 points -2.7 to -0.5 | 13,970 | NCT02993406 Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo |
| Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With Time to First Occurrence of Coronary Revascularization | 435 of 6,992 529 of 6,978 | -1.4 points -2.2 to -0.5 | 13,970 | NCT02993406 Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo |
| Bempedoic Acid 180 mg vs Placebo Comparator: deaths from any cause | 437 of 7,001 420 of 6,964 | 0.2 points -0.6 to 1.0 | 13,965 | NCT02993406 Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo |
| Bempedoic Acid 180 mg vs Placebo Comparator: serious adverse events | 1,767 of 7,001 1,733 of 6,964 | 0.4 points -1.1 to 1.8 | 13,965 | NCT02993406 Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo |
| Phase I: Observational, Mother vs Phase I: Observational, Neonate: Post-discharge Readmission or Mortality | 231 of 7,060 349 of 6,891 | -1.8 points -2.5 to -1.1 | 13,951 | NCT05730387 Smart Discharges for Mom & Baby |
| Apixaban vs Warfarin: Number of Participants Who Continued Treatment With Apixaban or Warfarin Following Discharge From the Hospital | 11,966 of 11,966 1,979 of 1,979 | 0.0 points -0.0 to 0.2 | 13,945 | NCT05795062 Treatment Patterns Among Patients With Venous Thromboembolism in the United States |
| Zoster-022 GSK1437173A Group vs Zoster-022 Placebo Group: Number of Subjects With SAEs Related to Study Participation or Concomitant GSK Medication | 57 of 6,950 84 of 6,950 | -0.4 points -0.7 to -0.1 | 13,900 | NCT01165229 Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older |
| Zoster-022 GSK1437173A Group vs Zoster-022 Placebo Group: Number of Subjects With Fatal Serious Adverse Events (SAEs) | 426 of 6,950 459 of 6,950 | -0.5 points -1.3 to 0.3 | 13,900 | NCT01165229 Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older |
| Zoster-022 GSK1437173A Group vs Zoster-022 Placebo Group: deaths from any cause | 426 of 6,950 459 of 6,950 | -0.5 points -1.3 to 0.3 | 13,900 | NCT01165229 Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older |
| Zoster-022 GSK1437173A Group vs Zoster-022 Placebo Group: serious adverse events | 1,153 of 6,950 1,214 of 6,950 | -0.9 points -2.1 to 0.4 | 13,900 | NCT01165229 Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older |
| Ticagrelor 90 mg bd vs Clopidogrel 75 mg od: Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke | 751 of 6,930 740 of 6,955 | 0.2 points -0.8 to 1.2 | 13,885 | NCT01732822 A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease |
| Clopidogrel 75mg od vs Ticagrelor 90mg bd: serious adverse events | 1,788 of 6,932 1,716 of 6,910 | 1.0 points -0.5 to 2.4 | 13,842 | NCT01732822 A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease |
| Prasugrel vs Clopidogrel: Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Rehospitalization for Cardiac Ischemic Events | 797 of 6,813 938 of 6,795 | -2.1 points -3.2 to -1.0 | 13,608 | NCT00097591 A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention |
| Prasugrel vs Clopidogrel: Number of Subjects Reaching the Composite Endpoint of All-Cause Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke | 692 of 6,813 822 of 6,795 | -1.9 points -3.0 to -0.9 | 13,608 | NCT00097591 A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention |
| Hydrochlorothiazide vs Chlorthalidone: Proportion of Participants Had a Composite Primary Outcome | 675 of 6,767 702 of 6,756 | -0.4 points -1.4 to 0.6 | 13,523 | NCT02185417 Diuretic Comparison Project |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=33
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02993406-442f76e9",
"title": "Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With Time to Cardiovascular Death",
"summary": "269 of 6992 against 257 of 6978; risk difference 0.2 points, 95% interval -0.5 to 0.8; NCT02993406, Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo",
"record": "/library/comparisons/NCT02993406-442f76e9",
"nct_id": "NCT02993406",
"kind": "outcome",
"participants": 13970,
"risk_difference": {
"value": 0.0016425027858067154,
"lower": -0.004686507646965966,
"upper": 0.007976651855784203
},
"group_1": "269 of 6,992",
"group_2": "257 of 6,978",
"difference": "0.2 points",
"interval": "-0.5 to 0.8",
"trial_title": "Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo"
},
{
"id": "NCT02993406-72055ce6",
"title": "Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With First Occurrence of Myocardial Infarction",
"summary": "261 of 6992 against 334 of 6978; risk difference -1.1 points, 95% interval -1.7 to -0.4; NCT02993406, Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo",
"record": "/library/comparisons/NCT02993406-72055ce6",
"nct_id": "NCT02993406",
"kind": "outcome",
"participants": 13970,
"risk_difference": {
"value": -0.010536342398109001,
"lower": -0.017266398231678016,
"upper": -0.0038411040442206876
},
"group_1": "261 of 6,992",
"group_2": "334 of 6,978",
"difference": "-1.1 points",
"interval": "-1.7 to -0.4",
"trial_title": "Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=34",
"request_id": "dt_a5sK3AHVIOyBd"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant